Dr Andrea Akinjo, Lagos University Teaching Hospital, Idi Araba, Nigeria

Host Institution: University of Manchester, Manchester, United Kingdom

PD-L1 expression in gastric cancer: a 10 year retrospective study (2010-2019)

Gastric cancer is the seventh most common cancer in the world and the fourth leading cause of cancer mortality worldwide. In Nigeria, it ranks as the eighth in mortality rates due to cancer. The tumour is diagnosed at an advanced stage in Nigeria leading to poor survival rates.

The prognosis of gastric cancer remains poor even though there have been recent advances in treatment. Immune therapy has recently become one of the important and promising treatment modalities for cancers including gastric cancer.

PD-L1 is one of the most promising targets of the immune therapy and there have been results showing good response to PD-L1 targeted therapy in other parts of the world. The aim of this study which is the first of its kind in Nigeria to the best of my knowledge, is to determine the proportion of gastric cancers that express PD-L1. This will lead to improved treatment choices for patients with gastric cancer in Nigeria as anti-PD-L1 targeted therapy can be considered as a potential treatment option for them.